Product Wiki · Recalls · Transport Canada

SUV recalled by HYUNDAI — recall 76997

Transport Canada · Canada · 2025-04-17

Compiled from an official source — the facts on this page are reproduced from the issuing authority’s own published notice, which is linked above. No AI-generated text appears on this page. How we use AI →
Agency
Transport Canada
Recall identifier
76997
Date of alert
2025-04-17
Country / jurisdiction
Canada
Risk type
recall
Product category
SUV
Product type
TC
Reported risk: This recall was replaced by Transport Canada recall no. 2025-193. Issue: On certain vehicles, a software problem in the integrated electronic brake could cause reduced braking when using the left-foot braking (LFB) feature. Note: This recall only affects certain Ioniq 5 N models. Safety Risk: Reduced braking can cause extended stopping distances and increase the risk of a crash. Corrective Actions: To reduce the safety risk, Hyundai recommends not to use the LFB feature until the recall repairs have been completed. Hyundai will notify owners by mail and send a wireless over-the-air software update to eligible vehicles to update the integrated electronic brake and vehicle control unit software. Alternatively, you may schedule an appointment to have the update performed at a Hyundai dealership. Note: Potential complications have been reported with the corrective actions and, as a result, the recall campaign is currently suspended. Hyundai is investigating the root cause and will provide an update once available. For owners who have already had the recall repairs completed, it is advised NOT TO USE the N e-SHIFT feature.
Primary source: https://recalls-rappels.canada.ca/en/alert-recall/transport-canada-recall-202505

Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.

ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.